As of 2026-10-02, the EV/EBITDA ratio of Fate Therapeutics Inc (FATE) is -2.04. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. FATE's latest enterprise value is 247.54 mil USD. FATE's TTM EBITDA according to its financial statements is -121.60 mil USD. Dividing these 2 quantities gives us the above FATE EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 11.8x - 14.6x | 13.4x |
| Forward P/E multiples | 14.5x - 18.4x | 16.3x |
| Fair Price | (14.91) - (15.08) | (15.32) |
| Upside | -748.2% - -755.5% | -765.9% |
| Date | EV/EBITDA |
| 2026-09-30 | -2.10 |
| 2026-09-29 | -2.11 |
| 2026-09-28 | -2.11 |
| 2026-09-25 | -2.08 |
| 2026-09-24 | -2.06 |
| 2026-09-23 | -2.16 |
| 2026-09-22 | -2.30 |
| 2026-09-21 | -2.26 |
| 2026-09-18 | -2.26 |
| 2026-09-17 | -2.25 |
| 2026-09-16 | -2.17 |
| 2026-09-15 | -2.08 |
| 2026-09-14 | -2.07 |
| 2026-09-11 | -2.05 |
| 2026-09-10 | -2.06 |
| 2026-09-09 | -2.17 |
| 2026-09-08 | -2.23 |
| 2026-09-04 | -2.21 |
| 2026-09-03 | -2.15 |
| 2026-09-02 | -2.18 |
| 2026-09-01 | -2.16 |
| 2026-08-31 | -2.12 |
| 2026-08-28 | -2.16 |
| 2026-08-27 | -2.27 |
| 2026-08-26 | -2.29 |
| 2026-08-25 | -2.28 |
| 2026-08-24 | -2.17 |
| 2026-08-21 | -2.06 |
| 2026-08-20 | -2.18 |
| 2026-08-19 | -2.37 |
| 2026-08-18 | -2.28 |
| 2026-08-17 | -2.34 |
| 2026-08-14 | -2.29 |
| 2026-08-13 | -2.25 |
| 2026-08-12 | -2.44 |
| 2026-08-11 | -2.46 |
| 2026-08-10 | -2.48 |
| 2026-08-07 | -2.51 |
| 2026-08-06 | -2.22 |
| 2026-08-05 | -2.32 |
| 2026-08-04 | -2.29 |
| 2026-08-03 | -2.23 |
| 2026-07-31 | -2.18 |
| 2026-07-30 | -2.24 |
| 2026-07-29 | -2.09 |
| 2026-07-28 | -2.05 |
| 2026-07-27 | -2.16 |
| 2026-07-24 | -2.14 |
| 2026-07-23 | -2.25 |
| 2026-07-22 | -2.30 |